

FIG. 1




FIG. 2




FIG. 3










FIG. 4







4/21




FIG. 11




FIG. 12




FIG. 13








FIG. 14


5/21



6/21


FIG. 17FIG. 18

7/21


FIG. 19

8/21



PROFIL DE LIBERATION IN VIVO DES INSERTS DE
DEXAMETHASONE (10 %) ADMINISTRE CHEZ LE
RAT EN SOUS-CUTANE.

FIG. 20A

PROFIL DE LIBERATION IN VIVO DES INSERTS DE
DEXAMETHASONE (15 %) ADMINISTRE CHEZ LE
RAT EN INTRA-PERITONEAL.


FIG. 20B

9/21


FIG. 21AFIG. 21B

10/21

PROFIL DE LIBERATION DES INSERTS DE
DEXAMETHASONE (20 %) ADMINISTRE CHEZ LE
RAT EN SOUS-CUTANE.

FIG. 22A

PROFIL DE LIBERATION DES INSERTS DE
DEXAMETHASONE (20 %) ADMINISTRE CHEZ LE
RAT EN INTRA-PERITONEAL.

FIG. 22B

11/21

ETUDE PHARMACOCINETIQUE SUR LE CHIEN DE 12,8 mg DE
LA FORME SOLIDE DE L'ACETATE DE LANREOTIDE INJECTEE EN
INTRAMUSCULAIRE.






FIG. 23

12/21

FIG. 24A

ETUDES PHARMACOCINETIQUES SUR LE VOLONTAIRE SAIN DE LA FORME SOLIDE 12,8 mg DE L'ACETATE DE LANREOTIDE INJECTEE EN SOUS-CUTANE (24A) ET EN INTRAMUSCULAIRE (24B).

FIG. 24B

13/21

CONCENTRATION DE LANREOTIDE DANS LE SANG DE VOLONTAIRES
SAINS APRES UNE INJECTION INTRAMUSCULAIRE DE 40 mg DE
LANREOTIDE SOUS FORME SEMI-SOLIDE.








FIG. 25

14/21

FIG. 26FIG. 27

15/21


FIG.28FIG.29

16/21

FIG.30



t-0,1h,1j,2j,3j,7j,10j



t-0,1h,1j,2j,3j,7j,10j









FIG.31





17/21

FIG. 32FIG. 33



18/21

FIG. 34FIG. 35

19/21

FIG. 36FIG. 37

20/21



21/21




FIG.39